Tumor Markers In Biological Fluids Associated With Pregnancy

REFERENCES

• Farghaly S A. Tumor markers in gynecologic cancer. Gynecol Obstet Invest 1992; 34: 65–72
   PubMed Web of Science ®Google Scholar
• Raghavan D, Gibbs J, Nogueira Costa Rn, Kohn J, Orr A H, Barrett A, Peckham M J. The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. Br J Cancer 1980; 41: 191–194
   Web of Science ®Google Scholar
• Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma, borderline tumours, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol 1990; 39: 16–25
   PubMed Web of Science ®Google Scholar
• Verlooy H, Devos P, Janssens J, Mortelmans L, Gerits M, Bonte J, De Roo M. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125. Gynecol Obstet Invest 1991; 32: 55–58
   PubMed Web of Science ®Google Scholar
• Bieglmayer C, Szepesi T, Neunteufel W. Follow-up of metastatic breast cancer patients with a mucin-like carcinoma-associated antigen: comparison to CA15.3 and carcinoembryonic antigen. Cancer Lett 1988; 42: 199–206
   PubMed Web of Science ®Google Scholar
• Sarandakou A, Phocas I, Botsis D, Sikiotis K, Rizos D, Kalambokis D, Trakakis E, Chryssikopoulos A. Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. Eur J Gynaecol Oncol 1998; 19: 73–77
   PubMed Web of Science ®Google Scholar
• Khoo S K, Whitaker S, Jones I, Mackay E. Predictive value of serial carcinoembryonic antigen levels in long-term follow-up of ovarian cancer. Cancer 1979; 43: 2471–2478
   PubMed Web of Science ®Google Scholar
• Parente J T, Greston W M. Carcinoembryonic antigen levels in the diagnosis of malignant lesions of the abdominopelvic region. Surg Gynecol Obstet 1981; 153: 693–696
   PubMedGoogle Scholar
• Ng J S, Sturgeon C M, Seth J, Paterson G M, Roulston J E, Leonard R C. Serological markers for metastatic breast cancer. Dis Markers 1993; 11: 217–223
   PubMed Web of Science ®Google Scholar
• Kabawat S E, Bast R C, Welch W R, Knapp R C, Colvin R B. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Pathol 1983; 79: 98–104
   PubMed Web of Science ®Google Scholar
• O'Brien T J, Hardin J W, Bannon G A, Norris J S, Quirk J G, Jr. CA-125 antigen in human amniotic fluid and fetal membranes. Am J Obstet Gynecol 1986; 155: 50–55
   PubMed Web of Science ®Google Scholar
• Scambia G, Gadducci A, Benedetti Panici P B, Foti E, Ferdeghini M, Ferrandina G, Amoroso M, Castellani C, Facchini V, Mancuso S. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol 1994; 54: 292–297
   PubMed Web of Science ®Google Scholar
• Pras E, Willemse P H, Canrinus A A, de Bruijn H W, Sluiter W J, ten Hoor K A, Aalders J G, Szabo B G, de Vries E G. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys 2002; 52: 23–32
   PubMed Web of Science ®Google Scholar
• van Dalen A, van der Linde D L, Heering K J, van Oudalblas A B. How can treatment response be measured in breast cancer patients?. Anticancer Res 1993; 13: 1901–1904
   PubMed Web of Science ®Google Scholar
• Gion M, Mione R, Becciolini A, Balzi M, Correale M, Piffanelli A, Giovannini G, Saccani Jotti G, Fontanesi M. Relationship between cytosol TPS, TPA, and cell proliferation. Int J Biol Markers 1994; 9: 109–114
   PubMedGoogle Scholar
• Inaba N, Fukasawa L, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sato N, Sudo H, Bjorklund B, et al. Immunoradiometrical measurement of tissue polypeptide specific antigen (TPS) in normal, healthy, nonpregnant and pregnant Japanese women. Asia Oceania J Obstet Gynaecol 1993; 19: 459–466
   PubMedGoogle Scholar
• Giovagnoli M R, Valli C, Vecchione A, Vecchione A. Immunohistochemical expression of tissue polypeptide specific (TPS) antigen in normal and neoplastic tissues. Anticancer Res 1994; 14: 635–641
   PubMed Web of Science ®Google Scholar
• Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci 1986; 292: 25–29
   PubMed Web of Science ®Google Scholar
• Zeimet A G, Muller-Holzner E, Marth C R, Daxenbichler G, Dapunt O. Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril 1993; 59: 1028–1035
   PubMed Web of Science ®Google Scholar
• Crombach G, Scharl A, Vierbuchen M, Wurz H, Bolte A. Detection of squamous cell carcinoma antigen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix. Cancer 1989; 63: 1337–1342
   PubMed Web of Science ®Google Scholar
• Benagiano G, Thomas E J. Benign proliferative disorders of the female tract: a call for a special interest group. Hum Reprod 1992; 3: 291–292
   Google Scholar
• Jacobs I, Bast R C, Jr. The CA125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1–12
   PubMed Web of Science ®Google Scholar
• Abae M, Gibson M, Chapitis J, Riddick D H, Brumsted J R. CA-125 levels in human uterine fluid. Fertil Steril 1992; 57: 531–534
   PubMed Web of Science ®Google Scholar
• Briese V, Barten G, Strache R R, Buttner H H, Voss P. Detection of carcinoembryonic antigen (CEA) in cervico-vaginal irrigation fluids. Zentralbl Gynakol 1989; 111: 223–229
   PubMedGoogle Scholar
• Jimera P, Castilla J A, Ramirez J P, Gil T, Acebal M, Molina R, Herruzo A. Follicular fluid alpha-fetoprotein, carcinoembryonic antigen and CA-125 levels in relation to in vitro fertilization and gonadotropin and steroid hormone concentrations. Fertil Steril 1993; 59: 1257–1260
   PubMed Web of Science ®Google Scholar
• Phocas I, Sarandakou A, Rizos D, Dimitriadou F, Mantzavinos T, Zourlas P A. Tumour-associated antigens, CEA, CA 125 and SCC in serum and follicular fluid of stimulated and unstimulated cycles. Eur J Obstet Gynecol Reprod Biol 1994; 54: 131–136
   PubMed Web of Science ®Google Scholar
• Hunter V J, Weinberg J B, Haney A F, Soper J T, Lavin P, Metsch L, Knapp R C, Bast R C, Jr. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 1990; 36: 161–165
   PubMed Web of Science ®Google Scholar
• Fujii S, Konishi I, Nanbu Y, Nonogaki H, Kobayashi F, Sagawa N, Mori T, Endo K. Analysis of the levels of CA 125, carcinoembryonic antigen, and CA 19-9 in the cervical mucus for a detection of cervical adenocarcinoma. Cancer 1988; 62: 541–547
   PubMed Web of Science ®Google Scholar
• de Bruijn H W, van Beeck Calkoen-Carpay T, Jager S, Duk J M, Aalders J G, Fleuren G J. The tumor marker CA 125 is a common constituent of normal cervical mucus. Am J Obstet Gynecol 1986; 154: 1088–1091
   PubMed Web of Science ®Google Scholar
• Sarandakou A, Phocas I, Botsis D, Rizos D, Trakakis E, Chryssikopoulos A. Vaginal fluid and serum CEA, CA125 and SCC in normal conditions and in benign and malignant diseases of the genital tract. Acta Oncol 1997; 36: 755–759
   PubMed Web of Science ®Google Scholar
• Poulakis N, Sarandakou A, Rizos D, Phocas I, Kontozoglou T, Polyzogopoulos D. Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer 1991; 68: 1045–1049
   PubMed Web of Science ®Google Scholar
• Quirk J G, Brunson G L, Long C A, Bannon G A, Sanders M M, O'Brien T J. CA125 in tissues and amniotic fluid during pregnancy. Am J Obstet Gynecol 1988; 159: 644–649
   PubMed Web of Science ®Google Scholar
• Sarandakou A, Kontoravdis A, Kontogeorgi Z, Rizos D, Phocas I. Expression of CEA, CA-125 and SCC by biological fluids associated with pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 44: 215–220
   PubMed Web of Science ®Google Scholar
• Giannaki G, Sarandakou A, Rizos D, Xyni K, Protonotariou E, Phocas I. Mucin-like carcinoma-associated antigen in paired serum and breast milk samples of lactating mothers and sera of their neonates in the early postpartum period. Eur J Obstet Gynecol Reprod Biol 2002; 105: 120–123
   PubMed Web of Science ®Google Scholar
• Yu H, Diamandis E P. Prostate-specific antigen in milk of lactating women. Clin Chem 1995; 41: 54–58
   PubMed Web of Science ®Google Scholar
• Melegos D N, Yu H, Allen L C, Diamandis E P. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 1996; 29: 555–562
   PubMed Web of Science ®Google Scholar
• Diamandis E P, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24: 275–782
   PubMed Web of Science ®Google Scholar
• DiSaia P J, Creasman W T. Tumor immunology and other host defence mechanisms. Clinical Gynecologic Oncology, 3rd Ed. Mosby, St. Louis 1988; 560–613
   Google Scholar
• Lelle R J, Henkel E, Leinemann D, Goeschen K. Measurement of CEA, TPA, neopterin, CA125, CA15-3 and CA19-9, in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 1989; 27: 137–142
   PubMed Web of Science ®Google Scholar
• Inglot A D, Gelder F, Georgiadis J A. Tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system. Biotherapy 1988; 11: 27–37
   Google Scholar
• Cembrzynska-Nowak M, Szklarz E, Inglot A D. Modulation of cytokine production by a selenoorganic compound (AE-22) in hyperreactive or hyporeactive bronchoalveolar leukocytes of asthmatics or lung cancer patients. J Interferon Cytokine Res 1997; 17: 609–617
   PubMed Web of Science ®Google Scholar
• Cheli C D, Morris D L, Neaman I E, Dai J, Allard W J, Yeung K K. Measurement of four tumor marker antigens in the sera of pregnant women. J Clin Lab Anal 1999; 13: 35–39
   PubMed Web of Science ®Google Scholar
• Hamilton M S. Maternal immune responses to oncofetal antigens. J Reprod Immunol 1983; 5: 249–264
   PubMed Web of Science ®Google Scholar
• Redman C W. Immunology of the placenta. Clin Obstet Gynaecol 1986; 13: 469–499
   PubMed Web of Science ®Google Scholar
• Fleuren G J, Nap M, Aalders J G, Trimbos J B, de Bruijn H W. Explanation of the limited correlation between tumor CA125 content and serum CA125 antigen levels in patients with ovarian tumors. Cancer 1987; 60: 2437–2442
   PubMed Web of Science ®Google Scholar
• Halila H, Huhtala M L, Haglund C, Nordling S, Stenman U H. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer 1987; 56: 153–156
   PubMed Web of Science ®Google Scholar
• Gitlin D, Boesman M. Serum alpha-fetoprotein, albumin and gamma-G-globulin in the human conceptus. J Clin Invest 1966; 45: 1826–1838
   PubMed Web of Science ®Google Scholar
• Deutsch H F. Chemistry and biology of alpha-fetoprotein. Adv Cancer Res 1991; 56: 253–312
   PubMed Web of Science ®Google Scholar
• Chen H, Egan J O, Chiu J F. Regulation and activities of alpha-fetoprotein. Crit Rev Eukaryot Gene Expr 1997; 7: 11–41
   PubMed Web of Science ®Google Scholar
• Gitlin D, Perricelli A, Gitlin G M. Synthesis of α-fetoprotein by liver, yolk sac and gastrointestinal tract of the human conceptus. Cancer Res 1972; 32: 979–982
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Hiria H. Alpha-fetoprotein. Carcinoembryonic proteins: Recent progress, B Norgaard-Pedersen, N H Axelsen. Blackwell, London 1978; 3–36
   Google Scholar
• Newby D, Dalgliesh G, Lyall F, Aitken D A. Alphafetoprotein and alphafetoprotein receptor expression in the normal human placenta at term. Placenta 2005; 26: 190–200
   PubMed Web of Science ®Google Scholar
• Ay E, Kavak Z N, Elter K, Gokaslan H, Pekin T. Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust NZ J Obstet Gynaecol 2005; 45: 283–288
   PubMed Web of Science ®Google Scholar
• Thomas R L, Blakemore K J. Evaluation of elevations in maternal serum alpha-fetoprotein: a review. Obstet Gynecol Surv 1990; 45: 269–283
   PubMedGoogle Scholar
• Van Lith J M. First-trimester screening for fetal chromosomal abnormalities. Preliminary results. Dutch Working Party on Prenatal Diagnosis. Prenatal Diagnosis 1991; 11: 621–624
   PubMed Web of Science ®Google Scholar
• Canick J A, MacRae A R. Second trimester serum markers. Semin Perinatol 2005; 29: 203–208
   PubMed Web of Science ®Google Scholar
• Mizejewski G J. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv 2003; 58: 804–826
   PubMed Web of Science ®Google Scholar
• Oehr P, Bellmann O, Hamann D. Measurement of Tennessee antigen, carcinoembryonic antigen, tissue polypeptide antigen and alpha-feto-protein in body fluids associated with pregnancy. Clin Biochem 1982; 15: 13–16
   PubMed Web of Science ®Google Scholar
• Talerman A, van der Pompe W B, Haije W G, Baggerman L, Boekestein-Tjahjadi H M. Alpha-foetoprotein and carcinoembryonic antigen in germ cell neoplasms. Br J Cancer 1977; 35: 288–291
   PubMed Web of Science ®Google Scholar
• Kohn J, Orr A H, McElwain T J, Bentall M, Peckham M J. Serum-alpha1-fetoprotein in patients with testicular tumours. Lancet 1976; 1: 433–436
   Google Scholar
• Vaitukaitis J L. Human chorionic gonadotropin—a hormone secreted for many reasons. N Engl J Med 1979; 301: 324–326
   PubMed Web of Science ®Google Scholar
• Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides K H. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005; 192: 1761–1767
   PubMed Web of Science ®Google Scholar
• Cole L A, Shahabi S, Oz U A, Bahado-Singh R O, Mahoney M J. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: a new basis for gestational Down syndrome screening. Clin Chem 1999; 45: 2109–2119
   PubMed Web of Science ®Google Scholar
• Cuckle H S, Shahabi S, Sehmi I K, Jones R, Cole L A. Maternal urine hyperglycosylated hCG in pregnancies with Down syndrome. Prenat Diagn 1999; 19: 918–920
   PubMed Web of Science ®Google Scholar
• Pandian R, Cole L A, Palomaki G E. Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening. Clin Chem 2004; 50: 1433–1435
   PubMed Web of Science ®Google Scholar
• Gold P, Freedman S O. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122: 467–481
   PubMed Web of Science ®Google Scholar
• Gadler H, Bremme K, Wahren B, Hammarstrom S. CEA and NCA in amniotic fluid in normal and abnormal pregnancies. Cancer 1978; 42: 1579–1584
   PubMed Web of Science ®Google Scholar
• Lindgren J. Carcinoembryonic antigen in fetal tissues and maternal serum. Acta Pathol Microbiol Scand [A] 1980; 88: 49–53
   PubMedGoogle Scholar
• Touitou Y, Darbois Y, Bogdan A, Auzeby A, Keusseoglou S. Tumour marker antigens during menses and pregnancy. Br J Cancer 1989; 60: 419–420
   PubMed Web of Science ®Google Scholar
• Schrocksnadel H, Daxenbichler G, Artner E, Steckel-Berger G, Dapunt O. Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest 1993; 35: 204–208
   PubMed Web of Science ®Google Scholar
• Nap M, Mollgard K, Burtin P, Fleuren G J. Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 1998; 9: 145–153
   Google Scholar
• Go V LW, Amnon H V, Holtmuler K H, Krag E, Philips S F. Quantification of carcinoembryonic antigen-like activities in normal human gastrointestinal secretions. Cancer 1975; 36: 2346–2350
   PubMed Web of Science ®Google Scholar
• Lolis D, Baltoyiannis P, Messinis I E. Carcinoembryonic antigen in high risk pregnancies. Int J Gynaecol Obstet 1984; 22: 5–9
   PubMed Web of Science ®Google Scholar
• Messinis I E, Milingos S, Lolis D, Diakomanolis E, Antoniou K, Chrysikou M, Kaskarelis D. Carcinoembryonic antigen (CEA) in normal and pre-eclamptic pregnancies (values in maternal blood, amniotic fluid and umbilical cord blood). Eur J Obstet Gynecol Reprod Biol 1980; 10: 351–359
   PubMed Web of Science ®Google Scholar
• Tayyar M, Tutus A. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA. Int J Fertil Womens Med 1999; 44: 256–259
   PubMedGoogle Scholar
• Kiran G, Kiran H, Guler F L, Ekerbicer H C, Kilinc M. Maternal serum and umbilical cord tumor marker levels at term pregnancy. Acta Obstet Gynecol Scand 2005; 84: 85–89
   PubMed Web of Science ®Google Scholar
• Gadler H, Wahren B, Lindsten J, Bremme K, Malmqvist E. Carcinoembryonic antigen in amniotic fluid. Acta Med Scand 1977; 201: 411–413
   PubMedGoogle Scholar
• Icard P, Regnard I F, Essomba A, Panebianco V, Magdaleinat P, Levasseur P. Preoperative carcinoembryonic antigen level a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 1994; 58: 811–814
   PubMed Web of Science ®Google Scholar
• Ryu J S, Lee H J, Cho J H, Han H S, Lee H L. The implication of elevated carcinoembryonic antigen level in pleural fluid of patients with non-malignant pleural effusion. Respirology 2003; 8: 487–491
   PubMed Web of Science ®Google Scholar
• Greenstein A J, Panvelliwalla D K, Katz L B, Heimann T M, Donnelly J, Pertsimlidis D, Geller S, Smith H, Aufses A H, Jr. Tissue carcinoembryonic antigen, dysplasia, and disease duration in colonic inflammatory bowel disease. Am J Gastroenterol 1982; 77: 212–215
   PubMed Web of Science ®Google Scholar
• Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 1996; 42: 564–575
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr., Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–1337
   PubMed Web of Science ®Google Scholar
• Magdelenat H. Tumour markers in oncology: past, present ant future. J Immunol Methods 1992; 150: 133–143
   PubMed Web of Science ®Google Scholar
• Touitou Y, Bogdan A. Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol 1988; 24: 1083–1091
   PubMedGoogle Scholar
• Barbati A, Lauro V, Orlacchio A, Cosmi E V. Immunoblotting characterization of CA 125 in biological fluids: difference between pregnancy and cancer CA 125 origin. Anticancer Res 1996; 16: 3621–3624
   PubMed Web of Science ®Google Scholar
• Barbati A, Anceschi M M, Alberti P, Pomili G, Di Renzo G C, Cosmi E V. Ontogeny of CA 125 antigen in pregnancy: immunoradiometric determination in amniotic fluid and immunohistochemical localization in fetal membranes. Am J Obstet Gynecol 1989; 160: 514–517
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr., Xu F J, Yu Y H, Barnhill S, Zhang Z, Mills G B. CA 125: the past and the future. Int J Biol Markers 1998; 13: 179–187
   PubMed Web of Science ®Google Scholar
• Takeshima N, Suminami Y, Takeda O, Abe H, Kato H. Origin of CA125 and SCC antigen in human amniotic fluid. Asia Oceania J Obstet Gynaecol 1993; 19: 199–204
   PubMedGoogle Scholar
• Lahdenne P, Pitkanen S, Rajantie J, Kuusela P, Siimes M A, Lanning M, Heikinheimo M. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatric Res 1995; 38: 797–801
   PubMed Web of Science ®Google Scholar
• Niloff J M, Knapp R C, Schaetzl E, Reynolds C, Bast R C, Jr. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984; 64: 703–707
   PubMed Web of Science ®Google Scholar
• Halila H, Stenman U H, Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327–1329
   PubMed Web of Science ®Google Scholar
• Pittaway D E, Rondinone D, Miller K A, Barnes K. Clinical evaluation of CA-125 concentrations as a prognostic factor for pregnancy in infertile women with surgically treated endometriosis. Fertil Steril 1995; 64: 321–324
   PubMed Web of Science ®Google Scholar
• Itahashi K, Inaba N, Fukuzawa I, Takamizawa H. Immunoradiometrical measurement of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) in pregnancy and at delivery. Arch Gynecol Obstet 1988; 243: 191–197
   PubMed Web of Science ®Google Scholar
• Jacobs I J, Fay T N, Yovich J, Stabile I, Frost C, Turner J, Oram D H, Grudzinskas J G. Serum levels of CA 125 during the first trimester of normal outcome, ectopic and anembryonic pregnancies. Hum Reprod 1990; 5: 116–122
   PubMed Web of Science ®Google Scholar
• Scarpellini F, Mastrone M, Sbracia M, Scarpellini L. Serum CA 125 and first trimester abortion. Int J Gynaecol Obstet 1995; 49: 259–264
   PubMed Web of Science ®Google Scholar
• Fiegler P, Katz M, Kaminski K, Rudol G. Clinical value of a single CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J Reprod Med 2003; 48: 982–988
   PubMed Web of Science ®Google Scholar
• Schmidt T, Rein D T, Foth D, Eibach H W, Kurbacher C M, Mallmann P, Romer T. Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 97: 168–173
   PubMed Web of Science ®Google Scholar
• Wenstrom K D, Owen J, Boots L. Second-trimester maternal serum CA-125 versus estriol in the multiple-marker screening test for Down syndrome. Obstet Gynecol 1997; 89: 359–363
   PubMed Web of Science ®Google Scholar
• Hogdall C K, Hogdall E V, Arends J, Norgaard-Pedersen B, Smidt-Jensen S, Larsen S O. CA-125 as a maternal serum marker for Down's syndrome in the first and second trimester. Prenat Diagn 1992; 12: 223–227
   PubMed Web of Science ®Google Scholar
• Van Blerk M, Smitz J, De Catte L, Kumps C, Van Der Elst J, Van Steirteghem A C. Second-trimester cancer antigen 125 and Down's syndrome. Prenat Diagn 1992; 12: 1062–1066
   PubMed Web of Science ®Google Scholar
• Van Lith J M, Mantingh A, De Bruijn H W. Maternal serum CA 125 levels in pregnancies with chromosomally-normal and-abnormal fetuses. Dutch Working Party on Prenatal Diagnosis. Prenat Diagn 1993; 13: 1123–1131
   PubMed Web of Science ®Google Scholar
• Sapir O, Holcberg G, Segal D, Gohar J, Huleihal M, Katz M, Mazor M. Maternal serum concentrations of CA-125 in second trimester pregnancy complicated by congenital fetal anomalies. Eur J Obstet Gynecol Reprod Biol 1999; 87: 133–136
   PubMed Web of Science ®Google Scholar
• Spencer K, Muller F, Aitken D A. Amniotic fluid and maternal serum levels of CA 125 in pregnancies affected by Down syndrome: a re-evaluation of the role of CA 125 in Down syndrome screening. Prenat Diagn 1997; 17: 701–706
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamane Y, Yoshino K, Shibukawa I, Matsunaga I, Kitao M. Studies on serum CA 125 levels in pregnant women. Nippon Sanka Fujinka Gakkai Zasshi 1985; 37: 1931–1934
   PubMedGoogle Scholar
• Hegab H M, Schindler A E, Rizk M, Ramadan M. Evaluation of tumour markers in molar pregnancy. Arch Gynecol Obstet 2003; 268: 151–154
   PubMedGoogle Scholar
• Hardardottir H, Parmley T H, Quirk J G, Jr., Sanders M M, Miller F C, O'Brien T J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 1990; 163: 1925–1931
   PubMed Web of Science ®Google Scholar
• De Bruijn H A, Duk M J, Fleuren G J, Kravis M, ten Hoor K A, Aaldress J G. The tumor markers CA-125 and SCC in gynaecological oncology. Scand J Clin Lab Invest 1988; 190: 36–39
   Google Scholar
• Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621–1628
   PubMed Web of Science ®Google Scholar
• Cataltepe S, Gornstein E R, Schick C, Kamachi Y, Chatson K, Fries J, Silverman G A, Upton M P. Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas. J Histochem Cytochem 2000; 48: 113–122
   PubMed Web of Science ®Google Scholar
• Dibbelt L, Knuppen R, Bobrowski A. Squamous cell carcinoma antigen immunoactivity is normal in maternal serum but high and increasing in amniotic fluid during pregnancy. Clin Chem 1992; 38: 1261–1262
   Web of Science ®Google Scholar
• Molina R, Filella X, Torres M D, Ballesta A M, Mengual P, Cases A, Balaque A. SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990; 36: 251–254
   PubMed Web of Science ®Google Scholar
• Botsis D, Sarandakou A, Kassanos D, Kontoravdis A, Rizos D, Protonotariou E, Phocas I, Creatsas G. Breast cancer markers during normal pregnancy. Anticancer Res 1999; 19: 3539–3542
   PubMed Web of Science ®Google Scholar
• Panidis D, Vlassis G, Matalliotakis J, Skiadopoulos S, Kalogeropoulos A. Serum levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 in patients with endometriosis. J Endocrinol Invest 1988; 11: 801–804
   PubMed Web of Science ®Google Scholar
• Schlageter M H, Larghero J, Cassinat B, Toubert M E, Borschneck C, Rain I D. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy. Clin Chem 1998; 44: 1995–1998
   PubMed Web of Science ®Google Scholar
• Bon G G, Kenemans P, Verstraeten A A, Go S, Philipi P A, van Kamp G J, van Geijn H P, van Vugt J M. Maternal serum CA 125 and CA 15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther 2001; 16: 166–172
   PubMed Web of Science ®Google Scholar
• Correale M, Abbate I, Dragone C D, Tedone T, Musci M D, Gargano G, Catino A M, Bafunno A M, Grossi B. Behaviour of four serum tumor markers in pregnant women. Int J Biol Markers 1993; 7: 198–199
   Google Scholar
• Hilkens J, Bujis F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, van der Valk M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984; 34: 197–206
   PubMed Web of Science ®Google Scholar
• Bieglmayer C, Szepesi T, Neunteufel W, Nowotny C. MCA, a monoclonal-antibody-defined breast-tumor-associated antigen and its relation to CA 15.3. Tumour Biol 1989; 12: 232–242
   Google Scholar
• Silver H K, Archibald B L, Ragaz J, Coldman A J. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma. Cancer Res 1991; 51: 1904–1909
   PubMed Web of Science ®Google Scholar
• Strous G J, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 1992; 27: 57–92
   PubMed Web of Science ®Google Scholar
• Schutter E M, Davelaar E M, van Kamp G J, Verstraeten R A, Kenemans P, Verheijen R H. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002; 187: 385–392
   PubMed Web of Science ®Google Scholar
• Maurer A, Burckhardt J. Biochemistry and molecular biology of MCA. Int J Biol Markers 1993; 8: 108–112
   PubMedGoogle Scholar
• Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, Grundler S, Gregorits M, Strasser M. CA15.3, MCA, CAM26, CAM29, are members of a polymorphic family of mucin-like glycoproteins. Tumour Biol 1991; 12: 138–148
   PubMedGoogle Scholar
• Sarandakou A, Rizos D, Botsis D, Kassanos D, Thomopoulos P, Protonotariou E, Phocas I. Mucin-like carcinoma-associated antigen (MCA) during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 96: 51–54
   PubMed Web of Science ®Google Scholar
• Putz I, Lang G, Winkler M, Rath W. Serum concentrations of the MCA tumor marker during pregnancy. Zentralbl Gynakol 1996; 118: 409–411
   PubMedGoogle Scholar
• Boccardo F, Bombardieri E, Zanardi S, Valenti G, Zanaboni F, Valtolina M, Seregni E, Crippa F. Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA. Int J Biol Markers 1991; 6: 12–20
   PubMedGoogle Scholar
• Inaba N, Fugazama I, Ota Y, Nito A, Ijichi M, Sato N, Takamizama H. Tissue polypeptide antigen and cancer antigen 125 in pregnancy. These two cancer-related antigens are oncofetal?. Acta Obstet Gynaecol Jpn 1985; 37: 2139–2140
   Google Scholar
• Kassanos D, Botsis D, Rizos D, Kontoravdis A, Sikiotis K, Phocas I, Sarandakou A, Creatsas G. Tissue polypeptide specific antigen (TPS) throughout normal pregnancy. Anticancer Res 2000; 20: 2129–2132
   PubMed Web of Science ®Google Scholar
• Sarandakou A, Malamitsi-Puchner A, Protonotariou E, Rigopoulou U, Papagianni V, Creatsas G. Indicative markers of cell proliferation and apoptosis during the perinatal period. Am J Perinatol 2003; 20: 283–288
   PubMed Web of Science ®Google Scholar
• Rebhandl W, Felberbauer F X, Paya K, Rami B, Bancher-Todesca D, Bieglmayer C, Horcher E. Tissue polypeptide-specific antigen in pediatric patients: assessment of normal values. Med Pediatr Oncol 1997; 29: 218–221
   PubMedGoogle Scholar
• Rebhandl W, Paya K, Felberbauer F X, Fuchs R, Henkel J, Bieglmayer C, Horcher E. Tissue polypeptide-specific antigen (TPS) in pediatric malignancies. Anticancer Res 1997; 17: 2865–2868
   PubMed Web of Science ®Google Scholar
• van Dalen A. How to integrate serum tumor markers into clinical oncologic practice. Nutrition 1995; 11: 489–491
   PubMed Web of Science ®Google Scholar
• Kil P J, Goldschmidt H M, Wieggers B J, Karriakine O B, Studer U E, Whelan P, Hetherington J, de Reijke T M, Hoekstra J W, Collette L. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma. Eur Urol 2003; 43: 31–38
   PubMed Web of Science ®Google Scholar
• Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma. Cancer 1998; 82: 1850–1859
   PubMed Web of Science ®Google Scholar
• Skalli O, Goldman R D. Recent insights into the assembly, dynamics and function of intermediate filament networks. Cell Motil Cytoskeleton 1991; 19: 67–69
   PubMed Web of Science ®Google Scholar
• Bjorklund B. Tumor markers TPA, TPA-S, and cytokeratins: a working hypothesis. Tumordiagn u Ther 1992; 13: 78–80
   Web of Science ®Google Scholar
• Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, Bergman A C, Zetterberg A, Marberger M, Bjorklund P, Skern T, Einarsson R, Jornvall H. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309–314
   PubMedGoogle Scholar
• Bonfrer J M, Groeneveld E M, Korse C M, van Dalen A, Oomen L C, Ivanyi D. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumour Biol 1994; 15: 210–222
   PubMedGoogle Scholar
• Barak V, Goike H, Panaretakis K W, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37: 529–540
   PubMed Web of Science ®Google Scholar
• van Dalen A, van der Linde D L, Heering K J, van Oudalblas A B. How can treatment response be measured in breast cancer patients?. Anticancer Res 1993; 13: 1901–1904
   PubMed Web of Science ®Google Scholar
• Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B. Tumor markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 2002; 13: 1430–1437
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Einarsson R, Pahlman L, Graf W. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol. 1996; 35: 141–148
   PubMed Web of Science ®Google Scholar
• Bjorklund B, Einarsson R. TPS (tissue polypeptide specific antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer. Tumordiagn u Ther 1996; 17: 67–73
   Web of Science ®Google Scholar
• Fonseca E, Castanhas S, Sobrinho-Simoes M. Carbohydrate antigens as oncofetal antigens in papillary carcinoma of the thyroid gland. Endocr Pathol 1997; 8: 301–303
   PubMed Web of Science ®Google Scholar
• Hanisch F G, Uhlenbruck G, Peter-Katalinic J, Egge H. Structural studies on oncofetal carbohydrate antigens (CA 19-9, CA 50 and CA 125) carried by O-linked sialyloligosaccharides on human amniotic mucins. Carbohydr Res 1988; 178: 29–47
   PubMed Web of Science ®Google Scholar
• Inaudi P, Pasqui L, Torre G C, Severi F M, Centini G, Gioffre W, Danero S, D'Antona N. CA 125 and CA 19-9 in peritoneal, cyst and amniotic fluids. Med Oncol Tumor Pharmacother 1988; 5: 233–238
   PubMedGoogle Scholar
• Kobayashi F, Sagawa N, Nanbu Y, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T. Immunohistochemical localization and tissue levels of tumor-associated glycoproteins CA 125 and CA 19-9 in the decidua and fetal membranes at various gestational ages. Am J Obstet Gynecol 1989; 60: 1232–1238
   Google Scholar
• Hohlfeld P, Dang T T, Nahoul K, Daffos F, Forestier F. Tumour-associated antigens in maternal and fetal blood. Prenat Diagn 1994; 14: 907–912
   PubMed Web of Science ®Google Scholar
• Terracciano D, Mariano A, Macchia V, Di Carlo A. Analysis of glycoproteins in human colon cancers, normal tissues and in human colon carcinoma cells reactive with monoclonal antibody NCL-19-9. Oncol Rep 2005; 14: 719–722
   PubMed Web of Science ®Google Scholar
• Engelen M J, de Bruijn H W, Hollema H, ten Hoor K A, Willemse P H, Aalders J G, van der Zee A G. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 2000; 78: 16–20
   PubMed Web of Science ®Google Scholar
• Wang M C, Valenzuela L A, Murphy G P, Chu T M. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–163
   PubMedGoogle Scholar
• Watt K W, Lee P J, M'Timkulu T, Chan W P, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166–3170
   PubMed Web of Science ®Google Scholar
• Chu T M. Prostate-specific antigen and early detection of prostate cancer. Tumor Biol 1997; 18: 123–134
   PubMed Web of Science ®Google Scholar
• Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc 1999; 151: 209–213
   PubMedGoogle Scholar
• Yu H, Diamandis E P. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995; 41: 204–210
   PubMed Web of Science ®Google Scholar
• Diamandis E P, Yu H. New biological functions of prostate-specific antigen?. J Clin Endocrinol Metab 1995; 80: 1515–1517
   PubMed Web of Science ®Google Scholar
• Filella X, Molina M, Alcover J, Carretero P, Ballesta A M. Detection of nonprostatic PSA in serum and nonserum samples from women. Int J Cancer 1996; 68: 424–427
   PubMed Web of Science ®Google Scholar
• Malatesta M, Mannello F, Luchetti F, Marcheggiani F, Condemi L, Papa S, Gazzanelli G. Prostate-specific antigen synthesis and secretion by human placenta: a physiological kallikrein source during pregnancy. J Clin Endocrinol Metab 2000; 85: 317–321
   PubMed Web of Science ®Google Scholar
• Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994; 78: 1536–1539
   PubMed Web of Science ®Google Scholar
• Salamonsen L A. Matrix metalloproteinases and endometrial remodeling. Cell Biol Int 1994; 18: 1139–1144
   PubMed Web of Science ®Google Scholar
• Clements J, Mukhtar A, Yan S, Holland A. Kallikreins and kinins in inflammatory-like events in the reproductive tract. Pharmacol Res 1997; 35: 537–540
   PubMed Web of Science ®Google Scholar
• Wald N J, Hackshaw A K, Diamandis E P, Melegos D N. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimester of pregnancy. Pren Diagn 1999; 19: 674–67
   PubMed Web of Science ®Google Scholar
• Kamenov Z, Todorova M, Khristov V. Prostate-specific antigen (PSA) in women. Vutr Boles 2001; 33: 40–47
   PubMedGoogle Scholar
• Spencer K, Carpenter P. Is prostate specific antigen a marker for pregnancies affected by Down syndrome?. Clin Chem 1998; 44: 2362–2365
   PubMed Web of Science ®Google Scholar